Medeva gains as cancer drug gets U.S. approval

Article Abstract:

Medeva PLC's shares rose 2.2% on Sep. 30, 1998, following the news that it received U.S. regulatory license approval for its drug for bladder cancer. Shares of the British drug manufacturer closed at 92 pence ($1.57) in London, UK, increasing two pence, after the US Food and Drug Administration granted Medeva seven years of market exclusivity for its drug Valstar. Valstar is mainly used for the treatment of patients with carcinoma-in-situ, or CIS, which is one of the three kinds of bladder cancer. Medeva, which purchased the exclusive marketing rights of Valstar from Antra Pharmaceuticals Inc. in July 1997, intends to have a US roll-out of Valstar in January 1998.

Comment:

Shares rise 2.2% on 9/30/98 following news that it received US regulatory license approval for its drug for bladder cancer

Pharmaceutical Preparation Manufacturing, Anticancer Drugs, Antineoplastic agents, Medeva PLC, Article

---

U.K. tech IPO climbs 17% in debut

Article Abstract:

Wolfson Microelectronics PLC saw its share value rise by 17% in its initial public offering (IPO). The company's shares were priced at 210 pence (3.01 euros) per share.

Semiconductor industry, Going public (Securities), Initial public offerings, Company public offering, Miniature electronic equipment, Microelectronics, Wolfson Microelectronics Ltd.

---

Fidelity is top holder of Sumitomo Mitsui

Article Abstract:

Fidelity Investments' mutual funds controlled 5.16% of Sumitomo Mitsui Financial Group Inc.'s stocks. This was at the end of the September 2003 period.

Japan, Mutual fund industry, Fidelity Investments, Sumitomo Mitsui Financial Group Inc.

Similar abstracts:

• Abstracts: Renaissance or reburial? Fingering fingerprints. Fingering Fiat
• Abstracts: SEB's operating profit drops 32%. Volvo is due to post profit leap
• Abstracts: Toshiba's earnings soar on real estate, stake sale. Brisk Yen action is seen on rate move
• Abstracts: Waiting for the earnings storm. As rich-poor gap widens in the U.S., class mobility stalls: those in bottom rung enjoy better odds in Europe; how parents confer an edge; immigrants see fast advance
• Abstracts: SAP America names president and COO. Piloting Boeing's New Course

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.